MOLECULIN BIOTECH ($MBRX) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of -$0.69 per share, missing estimates of -$0.57 by $0.12. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $MBRX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MOLECULIN BIOTECH Hedge Fund Activity
We have seen 12 institutional investors add shares of MOLECULIN BIOTECH stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CETERA INVESTMENT ADVISERS added 70,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $68,152
- ARMISTICE CAPITAL, LLC added 27,586 shares (+9.5%) to their portfolio in Q4 2024, for an estimated $46,896
- CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. added 12,781 shares (+inf%) to their portfolio in Q1 2025, for an estimated $12,443
- XTX TOPCO LTD added 11,575 shares (+inf%) to their portfolio in Q1 2025, for an estimated $11,269
- UBS GROUP AG removed 8,939 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $8,703
- LPL FINANCIAL LLC added 4,865 shares (+11.8%) to their portfolio in Q1 2025, for an estimated $4,736
- GEODE CAPITAL MANAGEMENT, LLC added 4,033 shares (+18.3%) to their portfolio in Q1 2025, for an estimated $3,926
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
